New clinical research strategies for rare gynecologic malignancies

Current Opinion in Obstetrics and Gynecology

Volumn 27, Issue 1, 2015, Pages 53-57

  Ray Coquard, Isabelle ^a   Pujade Lauraine, Eric ^b   Ledermann, Jonathan A ^c  

^a UNIVERSITÉ LYON 1   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

clinical trial; gynecologic tumor; rare cancers; registry

Indexed keywords

CANCER INCIDENCE; CANCER REGISTRY; CANCER THERAPY; CLINICAL RESEARCH; GYNECOLOGIC CANCER; HUMAN; MEDICAL PRACTICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; TOTAL QUALITY MANAGEMENT; CLASSIFICATION; COOPERATION; FACTUAL DATABASE; FEMALE; GENITAL NEOPLASMS, FEMALE; INCIDENCE; MEDICAL RESEARCH; METHODOLOGY; RARE DISEASES; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; REGISTRIES; RESEARCH DESIGN;

EID: 84920846449     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000144     Document Type: Review

References (19)

1. Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47:2493-2511.
2. Ray-Coquard I, Weber B, Lotz JP, et al. Management of rare ovarian cancers: the experience of the French website Observatory for rare malignant tumours of the ovaries by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol 2010; 119:53-59.
3. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20:945-952.
4. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol 2010; 21:2377-2381.
5. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34:433-443.
6. GershensonDM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009; 114:48-52.
7. Berrington de González A, Green J. Cancer ICoESoC: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8097 women with squamous cell carcinoma and 1374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120:885-891.
8. Ledermann JA, Ray-Coquard I. Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges. Am Soc Clin Oncol Educ Book 2014; e282-e286.
9. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20:463-466.
10. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8:17.
11. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-1392.
12. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 2011; 12:852-861.
13. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-Arm, phase 2 study. Lancet Oncol 2013; 14:134-140.
14. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008; 100:1204-1214.
15. Sleijfer S, Wagner AJ. The challenge of choosing appropriate end points in single-Arm phase II studies of rare diseases. J Clin Oncol 2012; 30:896-898.
16. Rosner GL, Berry DA. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat Med 1995; 14:381-394.
17. Rosner GL. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20:4478-4484.
18. Trimble EL, Davis J, Disaia P, et al. Clinical trials in gynecological cancer. Int J Gynecol Cancer 2007; 17:547-556.
19. Keat N, Law K, Seymour M, et al. International rare cancers initiative. Lancet Oncol 2013; 14:109-110.